DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
DAPIVIRINE
3
Small molecule
Investigational
Unknown
Unknown
Acquired Immunodeficiency Syndrome; Infections; HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
DAPIVIRINE
×
Maximum Phase:
3
First Approval:
None
UNII:
TCN4MG2VXS
Molecule Type:
Small molecule
Molecular Formula:
C20H19N5
Molecular Weight:
329.41
AlogP:
4.76
PSA:
73.63
HBD:
2.0
HBA:
#RotB:
4.0
Source:
FIRIBASTAT
3
Small molecule
Investigational
Unknown
Unknown
Renal Insufficiency; Essential Hypertension; Heart Failure; Myocardial Infarction; Hypertension
Aminopeptidase A inhibitor
FIRIBASTAT
×
Maximum Phase:
3
First Approval:
None
UNII:
638KY4573I
Molecule Type:
Small molecule
Molecular Formula:
C8H20N2O6S4
Molecular Weight:
368.52
AlogP:
-0.42
PSA:
160.78
HBD:
4.0
HBA:
#RotB:
11.0
Source:
RELACORILANT
3
Small molecule
Investigational
Unknown
Unknown
Adrenal Cortex Neoplasms; Liver Diseases; Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Adrenocortical Hyperfunction; Carcinoma, Pancreatic Ductal; Cushing Syndrome
Glucocorticoid receptor antagonist
RELACORILANT
×
Maximum Phase:
3
First Approval:
None
UNII:
2158753C7E
Molecule Type:
Small molecule
Molecular Formula:
C27H22F4N6O3S
Molecular Weight:
586.57
AlogP:
4.06
PSA:
102.98
HBD:
0.0
HBA:
#RotB:
5.0
Source:
CARBOPLATINE
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CARBOPLATINE
×
Maximum Phase:
3
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLOMOXEF
3
Small molecule
Investigational
Unknown
Unknown
Bacterial Infections; Urinary Tract Infections
Bacterial penicillin-binding protein inhibitor
FLOMOXEF
×
Maximum Phase:
3
First Approval:
None
UNII:
V9E5U5XF42
Molecule Type:
Small molecule
Molecular Formula:
C15H18F2N6O7S2
Molecular Weight:
496.47
AlogP:
-1.29
PSA:
169.0
HBD:
3.0
HBA:
#RotB:
11.0
Source:
NORUCHOLIC ACID
3
Small molecule
Investigational
Unknown
Unknown
Non-alcoholic Fatty Liver Disease; Cholangitis, Sclerosing
Unknown
NORUCHOLIC ACID
×
Maximum Phase:
3
First Approval:
None
UNII:
8A5G600D9V
Molecule Type:
Small molecule
Molecular Formula:
C23H38O4
Molecular Weight:
378.55
AlogP:
4.09
PSA:
77.76
HBD:
3.0
HBA:
#RotB:
3.0
Source:
XR9576
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
XR9576
×
Maximum Phase:
3
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LEVOMENTHOL
3
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
LEVOMENTHOL
×
Maximum Phase:
3
First Approval:
None
UNII:
BZ1R15MTK7
Molecule Type:
Small molecule
Molecular Formula:
C10H20O
Molecular Weight:
156.27
AlogP:
2.44
PSA:
20.23
HBD:
1.0
HBA:
#RotB:
1.0
Source:
APABETALONE
3
Small molecule
Investigational
Unknown
Unknown
Fabry Disease; Kidney Failure, Chronic; Diabetes Mellitus; Hypertension, Pulmonary; Severe Acute Respiratory Syndrome; Coronary Disease
Bromodomain and extra-terminal motif (BET) inhibitor
APABETALONE
×
Maximum Phase:
3
First Approval:
None
UNII:
8R4A7GDZ1D
Molecule Type:
Small molecule
Molecular Formula:
C20H22N2O5
Molecular Weight:
370.41
AlogP:
2.6
PSA:
93.67
HBD:
2.0
HBA:
#RotB:
6.0
Source:
MAPRACORAT
3
Small molecule
Investigational
Unknown
Unknown
Eye Diseases; Psoriasis; Conjunctivitis, Allergic; Dermatitis, Atopic; Dry Eye Syndromes; Cataract
Glucocorticoid receptor agonist
MAPRACORAT
×
Maximum Phase:
3
First Approval:
None
UNII:
145V79YBVP
Molecule Type:
Small molecule
Molecular Formula:
C25H26F4N2O2
Molecular Weight:
462.49
AlogP:
5.69
PSA:
54.38
HBD:
2.0
HBA:
#RotB:
6.0
Source:
INOSINE
3
Small molecule
Investigational
Unknown
Unknown
HIV Infections; Melanoma; Amyotrophic Lateral Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Multiple System Atrophy; Myocardial Infarction; Neoplasms; Triple Negative Breast Neoplasms; Diabetic Neuropathies; Eye Diseases; Jaundice, Obstructive; Parkinson Disease; Stroke; Virus Diseases
Unknown
INOSINE
×
Maximum Phase:
3
First Approval:
None
UNII:
5A614L51CT
Molecule Type:
Small molecule
Molecular Formula:
C10H12N4O5
Molecular Weight:
268.23
AlogP:
-2.27
PSA:
133.49
HBD:
4.0
HBA:
#RotB:
2.0
Source:
GW-406381
3
Small molecule
Investigational
Unknown
Unknown
Pain; Arthritis, Rheumatoid; Osteoarthritis, Knee; Toothache
Cyclooxygenase-2 inhibitor
GW-406381
×
Maximum Phase:
3
First Approval:
None
UNII:
5Y869C2THE
Molecule Type:
Small molecule
Molecular Formula:
C21H19N3O3S
Molecular Weight:
393.47
AlogP:
3.87
PSA:
73.56
HBD:
0.0
HBA:
#RotB:
5.0
Source:
ZANDELISIB
3
Small molecule
Investigational
Unknown
Unknown
Leukemia, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular
PI3-kinase p110-delta subunit inhibitor
ZANDELISIB
×
Maximum Phase:
3
First Approval:
None
UNII:
8Z28M5SX0X
Molecule Type:
Small molecule
Molecular Formula:
C31H38F2N8O
Molecular Weight:
576.7
AlogP:
5.23
PSA:
84.23
HBD:
1.0
HBA:
#RotB:
8.0
Source:
NICOBOXIL
3
Small molecule
Investigational
Unknown
Unknown
Low Back Pain
Unknown
NICOBOXIL
×
Maximum Phase:
3
First Approval:
None
UNII:
GSD5B9US0W
Molecule Type:
Small molecule
Molecular Formula:
C12H17NO3
Molecular Weight:
223.27
AlogP:
2.06
PSA:
48.42
HBD:
0.0
HBA:
#RotB:
7.0
Source:
PROPIVERINE
3
Small molecule
Investigational
Unknown
Unknown
Urinary Bladder, Overactive; Polyuria; Urinary Incontinence
Unknown
PROPIVERINE
×
Maximum Phase:
3
First Approval:
None
UNII:
468GE2241L
Molecule Type:
Small molecule
Molecular Formula:
C23H29NO3
Molecular Weight:
367.49
AlogP:
3.99
PSA:
38.77
HBD:
0.0
HBA:
#RotB:
7.0
Source:
LACTOSE MONOHYDRATE
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LACTOSE MONOHYDRATE
×
Maximum Phase:
3
First Approval:
None
UNII:
EWQ57Q8I5X
Molecule Type:
Small molecule
Molecular Formula:
C12H24O12
Molecular Weight:
360.31
AlogP:
-5.4
PSA:
189.53
HBD:
8.0
HBA:
#RotB:
4.0
Source:
VERCIRNON SODIUM
3
Small molecule
Investigational
Unknown
Unknown
Crohn Disease
Unknown
VERCIRNON SODIUM
×
Maximum Phase:
3
First Approval:
None
UNII:
9NQF0M8R0M
Molecule Type:
Small molecule
Molecular Formula:
C22H20ClN2NaO4S
Molecular Weight:
466.92
AlogP:
4.3
PSA:
90.18
HBD:
1.0
HBA:
#RotB:
5.0
Source:
EPROTIROME
3
Small molecule
Investigational
Unknown
Unknown
Hypercholesterolemia; Lipid Metabolism Disorders; Hyperlipoproteinemia Type II
Thyroid hormone receptor beta-1 agonist
EPROTIROME
×
Maximum Phase:
3
First Approval:
None
UNII:
958AQ7B6R1
Molecule Type:
Small molecule
Molecular Formula:
C18H17Br2NO5
Molecular Weight:
487.14
AlogP:
5.25
PSA:
95.86
HBD:
3.0
HBA:
#RotB:
6.0
Source:
LANABECESTAT
3
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Renal Insufficiency; Alzheimer Disease
Beta-secretase 1 inhibitor
LANABECESTAT
×
Maximum Phase:
3
First Approval:
None
UNII:
X8SPJ492VF
Molecule Type:
Small molecule
Molecular Formula:
C26H28N4O
Molecular Weight:
412.54
AlogP:
4.24
PSA:
72.86
HBD:
1.0
HBA:
#RotB:
2.0
Source:
PUTRESCINE
3
Small molecule
Investigational
Unknown
Unknown
Cicatrix
Unknown
PUTRESCINE
×
Maximum Phase:
3
First Approval:
None
UNII:
V10TVZ52E4
Molecule Type:
Small molecule
Molecular Formula:
C4H12N2
Molecular Weight:
88.15
AlogP:
-0.32
PSA:
52.04
HBD:
2.0
HBA:
#RotB:
3.0
Source:
ANAPRAZOLE
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ANAPRAZOLE
×
Maximum Phase:
3
First Approval:
None
UNII:
W6OO9ZB0FC
Molecule Type:
Small molecule
Molecular Formula:
C21H24N2O4S
Molecular Weight:
400.5
AlogP:
3.53
PSA:
73.44
HBD:
1.0
HBA:
#RotB:
8.0
Source:
TALAPORFIN
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
TALAPORFIN
×
Maximum Phase:
3
First Approval:
None
UNII:
P4ROX5ELT2
Molecule Type:
Small molecule
Molecular Formula:
C38H41N5O9
Molecular Weight:
711.77
AlogP:
5.95
PSA:
235.66
HBD:
7.0
HBA:
#RotB:
12.0
Source:
RIVOCERANIB MESYLATE
3
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Adenocarcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Osteosarcoma; Sarcoma; Small Cell Lung Carcinoma; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Stomach Neoplasms
Vascular endothelial growth factor receptor 2 inhibitor
RIVOCERANIB MESYLATE
×
Maximum Phase:
3
First Approval:
None
UNII:
TK02X14ASJ
Molecule Type:
Small molecule
Molecular Formula:
C25H27N5O4S
Molecular Weight:
493.59
AlogP:
4.68
PSA:
90.7
HBD:
2.0
HBA:
#RotB:
6.0
Source:
ESMIRTAZAPINE
3
Small molecule
Investigational
Unknown
Unknown
Sleep Initiation and Maintenance Disorders
Unknown
ESMIRTAZAPINE
×
Maximum Phase:
3
First Approval:
None
UNII:
4685R51V7M
Molecule Type:
Small molecule
Molecular Formula:
C17H19N3
Molecular Weight:
265.36
AlogP:
2.48
PSA:
19.37
HBD:
0.0
HBA:
#RotB:
0.0
Source:
ISOMALT
3
Small molecule
Investigational
Unknown
Unknown
Inflammatory Bowel Diseases
Unknown
ISOMALT
×
Maximum Phase:
3
First Approval:
None
UNII:
S870P55O2W
Molecule Type:
Small molecule
Molecular Formula:
C12H24O11
Molecular Weight:
344.31
AlogP:
-5.76
PSA:
200.53
HBD:
9.0
HBA:
#RotB:
8.0
Source:
OCUFILCON D
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
OCUFILCON D
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RESINIFERATOXIN
3
Small molecule
Investigational
Unknown
Unknown
Cancer Pain; Morton Neuroma; Osteoarthritis, Knee; Pain, Intractable
Vanilloid receptor agonist
RESINIFERATOXIN
×
Maximum Phase:
3
First Approval:
None
UNII:
A5O6P1UL4I
Molecule Type:
Small molecule
Molecular Formula:
C37H40O9
Molecular Weight:
628.72
AlogP:
4.74
PSA:
120.75
HBD:
2.0
HBA:
#RotB:
8.0
Source:
SYN115
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SYN115
×
Maximum Phase:
3
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DAREXABAN
3
Small molecule
Investigational
Unknown
Unknown
Acute Coronary Syndrome; Atrial Fibrillation; Thromboembolism; Venous Thromboembolism
Coagulation factor X inhibitor
DAREXABAN
×
Maximum Phase:
3
First Approval:
None
UNII:
KF322K101S
Molecule Type:
Small molecule
Molecular Formula:
C27H30N4O4
Molecular Weight:
474.56
AlogP:
4.05
PSA:
94.14
HBD:
3.0
HBA:
#RotB:
6.0
Source:
RADIUM
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
RADIUM
×
Maximum Phase:
3
First Approval:
None
UNII:
W90AYD6R3Q
Molecule Type:
Small molecule
Molecular Formula:
Ra
Molecular Weight:
226.0
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
DENUFOSOL TETRASODIUM
3
Small molecule
Investigational
Unknown
Unknown
Macular Edema; Retinal Detachment; Rhinitis, Allergic, Perennial; Cystic Fibrosis
Purinergic receptor P2Y2 agonist
DENUFOSOL TETRASODIUM
×
Maximum Phase:
3
First Approval:
None
UNII:
82M942WZ4A
Molecule Type:
Small molecule
Molecular Formula:
C18H23N5Na4O21P4
Molecular Weight:
861.25
AlogP:
-2.87
PSA:
390.27
HBD:
9.0
HBA:
#RotB:
14.0
Source:
MK-0767
3
Small molecule
Investigational
Unknown
Unknown
Metabolic Syndrome; Diabetes Mellitus; Diabetes Mellitus, Type 2
Peroxisome proliferator-activated receptor alpha agonist
MK-0767
×
Maximum Phase:
3
First Approval:
None
UNII:
Y180U02GSB
Molecule Type:
Small molecule
Molecular Formula:
C20H17F3N2O5
Molecular Weight:
422.36
AlogP:
2.82
PSA:
93.73
HBD:
2.0
HBA:
#RotB:
6.0
Source:
FILGOTINIB
3
Small molecule
Investigational
Unknown
Unknown
Arthritis, Juvenile; Kidney Diseases; Inflammatory Bowel Diseases; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Sjogren's Syndrome; Uveitis; Arthritis, Psoriatic; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Spondylarthropathies; Spondylitis, Ankylosing
Tyrosine-protein kinase JAK1 inhibitor
FILGOTINIB
×
Maximum Phase:
3
First Approval:
None
UNII:
3XVL385Q0M
Molecule Type:
Small molecule
Molecular Formula:
C21H23N5O3S
Molecular Weight:
425.51
AlogP:
1.98
PSA:
96.67
HBD:
1.0
HBA:
#RotB:
5.0
Source:
FASUDIL
3
Small molecule
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis; Dementia; Retinal Vein Occlusion; Retinopathy of Prematurity; Cardiovascular Diseases
Rho-associated protein kinase inhibitor
FASUDIL
×
Maximum Phase:
3
First Approval:
None
UNII:
Q0CH43PGXS
Molecule Type:
Small molecule
Molecular Formula:
C14H17N3O2S
Molecular Weight:
291.38
AlogP:
1.22
PSA:
62.3
HBD:
1.0
HBA:
#RotB:
2.0
Source:
MARVELON
3
Small molecule
Investigational
Unknown
Unknown
Premenstrual Syndrome
Unknown
MARVELON
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C42H54O3
Molecular Weight:
606.89
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
1
2
…
147
148
149
150
151
152
153
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA